Safety tolerability and pharmacokinetics and pharmacodynamics of HL2351 a novel hybrid fc‐fused interleukin‐1 receptor antagonist in healthy subjects: A first‐in‐human study

摘要

We performed a first‐in‐human study with HL2351, a novel hybrid Fc‐fused interleukin (https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5878, to evaluate its tolerability, pharmacokinetics and pharmacodynamics (PD) after a single subcutaneous (SC) administration in healthy subjects.